We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Therapeutic Solutions International Inc (PK) | USOTC:TSOI | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00005 | 9.09% | 0.0006 | 0.0005 | 0.0006 | 0.0006 | 0.0005 | 0.0005 | 57,890,516 | 18:33:54 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 18, 2019
THERAPEUTIC SOLUTONS INTERNATIONAL, INC.
(Exact Name of Registrant as Specified in its Charter)
Nevada |
|
000-54554 |
|
45-1226465 |
(State or other jurisdiction of incorporation or organization) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification Number) |
4093 Oceanside Boulevard, Suite B |
Oceanside, California 92056 |
(Address of Principal Executive Offices and Zip Code) |
|
(760) 295-7208 |
(Issuer's telephone number) |
|
Not Applicable |
(Former Name or Former Address, if Changed Since Last Report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Entry into a Material Definitive Agreement.
On June 18, 2019, Jadi Cell, LLC, holder of a Convertible Note dated June 01, 2019, exercised their rights under the conversion for $153,552 converted into common shares of TSOI at 0.0016 per share for 95,970,000 common.
Item 9.01 Financial Statements and Exhibits.
No. |
|
Description |
|
Convertible Note between TSOI and Jadi Cell, LLC. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 18, 2019
THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.
By: /s/ Timothy Dixon
Timothy Dixon
Chief Executive Officer
1 Year Therapeutic Solutions (PK) Chart |
1 Month Therapeutic Solutions (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions